TrialsgrambetaRCTs are beautiful

Lin AI-ECG (potassium)

2026

AI-Enabled Electrocardiogram Alert for Potassium Imbalance Treatment: a Pragmatic Randomized Controlled Trial

In 14,989 emergency department patients, a real-time AI-ECG alert for hyper- or hypokalaemia did not improve rates of hyperkalaemia- and hypokalaemia-related treatment within three hours compared with usual care without alerts.

Result

Efficacy: Rate of hyperkalaemia-related treatment and rate of hypokalaemia-related treatment within three hours (two primary outcomes)HR 1.05 (95% CI 0.94-1.17) · P = 0.420

Below 1 favours usual care without alerts, above 1 favours a real-time AI-ECG alert for hyper- or hypokalaemia.

Event rates
Absolute difference
0.3 points

The absolute difference is derived from the event rates.

Also reported: Hypokalaemia-related treatment 2.1% vs 2.4% (HR 0.91, 95% CI 0.74–1.13; P=0.392). Among patients flagged by AI-ECG as hyperkalaemic, treatment 69.1% vs 41.6% (HR 2.23, 95% CI 1.44–3.46; P<0.001).

Original publication
Subtopic
Acute diagnosis & risk alerts
Design
Pragmatic open-label RCT with physician-level randomisation (70 emergency physicians, two hospitals)
Relevance
Important: one of several pillars.
Source
Lin C, et al. Nat Commun. 2026;17(1):159.doi 10.1038/s41467-025-66394-4

Discussion & critique

A negative AI-ECG trial: at the population level the alert did not change treatment of either potassium disorder, and benefit appeared only in the subgroup the AI actually flagged. It teaches that an alert for a condition routine laboratory testing already catches quickly has little room to add at scale, and that subgroup gains do not translate into trial-level effects. Open-label, physician-level randomisation in two hospitals carries a risk of contamination, and the endpoints are process measures rather than outcomes.